1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010). (10th December 2020) Authors: Yu, Evan; Park, Se Hoon; Huang, Yi-Hsiu; Bennamoun, Mostefa; Xu, Lu; Kim, Jeri; Antonarakis, Emmanuel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010). (9th November 2020) Authors: Yu, Evan; Park, Se Hoon; Huang, Yi-Hsiu; Bennamoun, Mostefa; Xu, Lu; Kim, Jeri; Antonarakis, Emmanuel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Ethnic minority status as social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early phase of the pandemic: a meta-analysis. Issue 11 (5th November 2021) Authors: Agyemang, Charles; Richters, Anke; Jolani, Shahab; Hendriks, Stevie; Zalpuri, Saurabh; Yu, Evan; Pijls, Bart; Prins, Maria; Stronks, Karien; Zeegers, Maurice P Journal: BMJ global health Issue: Volume 6:Issue 11(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. MP56-06 ASSOCIATIONS BETWEEN SKELETAL MUSCLE GAUGE AND SURVIVAL FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER: A NOVEL ASSESSMENT OF MUSCLE MASS AND QUALITY. (May 2022) Authors: Noonavath, Meghana; Mun, Kevin; Marquardt, J. Peter; Fintelmann, Florian J.; O'Malley, Ryan; Holt, Sarah K.; Dwyer, Erin; Maldonado, Reno; Diamantopoulos, Leonidas; Makrakis, Dimitrios; Laidlaw, Grace; Schade, George R.; Lin, Dan W.; Wright, Jonathan L.; Gore, John L.; Nyame, Yaw; Grivas, Petros;... Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e973 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PD10-06 A PHASE 1/2 STUDY OF RAPAMYCIN AND CISPLATIN/GEMCITABINE FOR TREATMENT OF PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (NCT01938573). (May 2022) Authors: Makrakis, Dimitrios; Roudier, Martine; Wang, Yan; Vakar-Lopez, Funda; Garcia, Jose; Dash, Atreya; Lin, Daniel; Schade, George; Mostaghel, Elahe A.; Cheng, Heather; Schweizer, Michael T.; Holt, Sarah K.; Gore, John L.; Yu, Evan; Lam, Hung-Ming; Wright, Jonathan L.; Montgomery, Bruce Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PD14-10 PROSPECTIVE EVALUATION OF A COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) IN MULTIDISCIPLINARY BLADDER CANCER CARE: FEASIBILITY AND IMPACT ON DECISIONAL CONFLICT. (May 2022) Authors: Psutka, Sarah; Gore, John; Holt, Sarah; Dwyer, Erin; Schade, George; Grivas, Petros; Hsieh, Andrew; Lee, John; Montgomery, R. Bruce; Schweizer, Michael; Yezefski, Todd; Yu, Evan; Chen, Jonathan; Liao, Jay; Weg, Emily; Zeng, Jing; Alving, Tristan; Jannat, Samia; Wright, Jonathan Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS?. (May 2022) Authors: Ghali, Fady; Roudier, Martine; Vakar-Lopez, Funda; Garcia, Jose; Wang, Yan; Ha, Gavin; Grivas, Petros; Lee, John; Yu, Evan; Montgomery, Bruce; Hsieh, Andrew; Wright, Jonathan; Lam, Hung-Ming Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e913 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Issue 7 (July 2021) Authors: Powles, Thomas; Csőszi, Tibor; Özgüroğlu, Mustafa; Matsubara, Nobuaki; Géczi, Lajos; Cheng, Susanna Y-S; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Morales Barrera, Rafael; Fléchon, Aude; Gunduz, Seyda; Loriot, Yohann; Rodriguez-Vida, Alejo; Mamtani, Ronac; Yu, Evan Y; Nam, Kijoeng; Imai... Journal: Lancet oncology Issue: Volume 22:Issue 7(2021) Page Start: 931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗